CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
- Written by PR Newswire
![]() |
SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2...
Read more: CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI